Your browser doesn't support javascript.
loading
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
de Blank, Peter M K; Gross, Andrea M; Akshintala, Srivandana; Blakeley, Jaishri O; Bollag, Gideon; Cannon, Ashley; Dombi, Eva; Fangusaro, Jason; Gelb, Bruce D; Hargrave, Darren; Kim, AeRang; Klesse, Laura J; Loh, Mignon; Martin, Staci; Moertel, Christopher; Packer, Roger; Payne, Jonathan M; Rauen, Katherine A; Rios, Jonathan J; Robison, Nathan; Schorry, Elizabeth K; Shannon, Kevin; Stevenson, David A; Stieglitz, Elliot; Ullrich, Nicole J; Walsh, Karin S; Weiss, Brian D; Wolters, Pamela L; Yohay, Kaleb; Yohe, Marielle E; Widemann, Brigitte C; Fisher, Michael J.
Afiliación
  • de Blank PMK; Department of Pediatrics, University of Cincinnati and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Gross AM; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Akshintala S; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Blakeley JO; Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Bollag G; Plexxikon Inc., Berkeley, California, USA.
  • Cannon A; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Dombi E; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Fangusaro J; Children's Hospital of Atlanta, Emory University and the Aflac Cancer Center, Atlanta, Georgia, USA.
  • Gelb BD; Department of Pediatrics and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Hargrave D; Department of Oncology, Great Ormond Street Hospital for Children, London, UK.
  • Kim A; Center for Neuroscience and Behavioral Medicine and Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
  • Klesse LJ; Department of Pediatrics, Division of Hematology/Oncology, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Loh M; Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.
  • Martin S; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Moertel C; Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
  • Packer R; Center for Neuroscience and Behavioral Medicine and Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
  • Payne JM; Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.
  • Rauen KA; Department of Pediatrics, University of California Davis, Sacramento, California, USA.
  • Rios JJ; Center for Pediatric Bone Biology and Translational Research, Scottish Rite for Children, Dallas, Texas, USA.
  • Robison N; Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA.
  • Schorry EK; Department of Pediatrics, University of Cincinnati and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Shannon K; Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.
  • Stevenson DA; Department of Pediatrics, Division of Medical Genetics, Stanford University, Stanford, California, USA.
  • Stieglitz E; Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.
  • Ullrich NJ; Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Walsh KS; Center for Neuroscience and Behavioral Medicine and Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
  • Weiss BD; Department of Pediatrics, University of Cincinnati and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Wolters PL; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Yohay K; Department of Neurology and Pediatrics, New York University Grossman School of Medicine, New York, New York, USA.
  • Yohe ME; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Widemann BC; Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.
  • Fisher MJ; Division of Oncology, The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Neuro Oncol ; 24(11): 1845-1856, 2022 11 02.
Article en En | MEDLINE | ID: mdl-35788692
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neurofibromatosis 1 / Neurofibroma Plexiforme / Quinasas de Proteína Quinasa Activadas por Mitógenos / Inhibidores de Proteínas Quinasas Tipo de estudio: Guideline Límite: Child / Humans Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neurofibromatosis 1 / Neurofibroma Plexiforme / Quinasas de Proteína Quinasa Activadas por Mitógenos / Inhibidores de Proteínas Quinasas Tipo de estudio: Guideline Límite: Child / Humans Idioma: En Revista: Neuro Oncol Asunto de la revista: NEOPLASIAS / NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido